Retina Risk
RetinaRisk is an Icelandic health-IT company developing AI-driven diabetic retinopathy screening for U.S. primary care providers, using computer vision on retinal fundus images in a market reimbursed under Medicare CPT code 92229, though its operations appear dormant with a parked website.
- Company typePrivate
- Founded2008
- HeadquartersReykjavík, Iceland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Retina Risk firmographics
Firmographics- Name
- Retina Risk
- Legal name
- RetinaRisk
- Website
- https://retinarisk.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- RetinaRisk is an Icelandic health-IT company developing AI-driven diabetic retinopathy screening for U.S. primary care providers, using computer vision on retinal fundus images in a market reimbursed under Medicare CPT code 92229, though its operations appear dormant with a parked website.
- Ownership category
- akta.pro rank
Where Retina Risk is headquartered
LocationHeadquarters
- HQ city
- Reykjavík
- HQ country
- Iceland
- HQ region
- Europe
Markets served
Retina Risk business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales
Go-to-market motion1 record
Retina Risk product offering
Product offeringCore offering
RetinaRisk offers an AI-driven diabetic retinopathy screening solution that analyzes retinal fundus images using computer vision to detect signs of disease. The product enables autonomous AI diagnostics in primary care settings where access to ophthalmologists is limited, and is positioned as eligible for reimbursement under Medicare CPT code 92229. It targets healthcare providers serving the 38.4 million U.S. residents affected by diabetes.
Differentiator
Problem solved
Functional benefit
Products and services
- RetinaRisk
Quantifiable outcome
- U.S. AI-driven diabetic retinopathy screening market projected to grow from USD 190.01M (2025) to USD 881.74M (2033) at 21.18% CAGR.
- +1 more outcomes
Companies that use Retina Risk
Customer profileSegments2 records
Ideal customer profiles1 record
Retina Risk technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
Retina Risk partnerships and signals
Strategic signalScale indicators3 records
Retina Risk competitors and assessment
Company assessmentDirect peers
- Eyenuk: Eyenuk (EyeArt) is a leading FDA-cleared autonomous AI platform for diabetic retinopathy screening, directly competing in the same CPT 92229 reimbursed primary-care use case that Retina Risk targets.
- Digital Diagnostics: Digital Diagnostics developed IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, and competes head-to-head with Retina Risk in primary-care screening.
- AEYE Health: AEYE Health offers FDA-cleared autonomous AI screening for diabetic retinopathy, targeting the same primary-care and U.S. market segment where Retina Risk is profiled.
- IRIS (Intelligent Retinal Imaging Systems): IRIS provides AI-enabled retinal screening services to primary care, directly overlapping with Retina Risk's value proposition of bringing specialist-grade screening to non-ophthalmology settings.
- Optomed: Optomed combines handheld fundus cameras with AI screening software for diabetic retinopathy, operating in the same AI-driven screening category as Retina Risk.
- RETINA-AI Health: RETINA-AI Health develops AI-based diabetic retinopathy screening tools explicitly named alongside Retina Risk in the U.S. market research, indicating overlapping customer and use-case focus.
Broad incumbents
- Topcon Healthcare: Topcon is a global ophthalmic imaging incumbent whose fundus camera and AI screening ecosystem compete for the same diabetic retinopathy screening workflows targeted by Retina Risk.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a major ophthalmic device and imaging incumbent with AI/retinal screening adjacencies, representing the broad established competitive backdrop for an AI DR screening vendor.
- iCare (Revenio Group): iCare, part of Revenio, produces retinal imaging devices and screening software, sitting in the same diabetic retinopathy ecosystem and explicitly named in Retina Risk's peer set.
Emerging players
- BeamMed: BeamMed is named alongside Retina Risk in the U.S. AI diabetic retinopathy screening market, suggesting a comparable early-stage or niche AI screening profile.
Market position
Customer concentration
Retina Risk financial estimates
Financial estimateRevenue estimate
Valuation estimate
Retina Risk leadership team
Management profileNumber of profiles
Profiles6 records
Retina Risk funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Retina Risk M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Retina Risk
What does Retina Risk do?
RetinaRisk offers an AI-driven diabetic retinopathy screening solution that analyzes retinal fundus images using computer vision to detect signs of disease. The product enables autonomous AI diagnostics in primary care settings where access to ophthalmologists is limited, and is positioned as eligible for reimbursement under Medicare CPT code 92229. It targets healthcare providers serving the 38.4 million U.S. residents affected by diabetes.
Is Retina Risk a public or private company?
Retina Risk is a private company. It is classified as founder individual operated bootstrapped and is currently closed.
When was Retina Risk founded?
Retina Risk was founded in 2008. It employs 1 to 10 people.
Where is Retina Risk based?
Retina Risk is headquartered in Reykjavík, Iceland, in the Europe region.
Who are Retina Risk's main competitors?
Direct peers on record are Eyenuk, Digital Diagnostics, AEYE Health, IRIS (Intelligent Retinal Imaging Systems), Optomed and RETINA-AI Health. Broad incumbents are Topcon Healthcare, Carl Zeiss Meditec and iCare (Revenio Group). BeamMed is listed as an emerging player.
Does Retina Risk have an API?
No public API is recorded for Retina Risk.